Related Experiment Videos
Committee for the protection of persons
Nathalie Brion1, Jean-Paul Demarez, Chantal Belorgey
1Centre Hospitalier de Versailles, Le Chesnay, France.
Therapie
|November 5, 2005
Summary
French law now requires favorable Committee for the Protection of Persons (CPP) opinions before authorizing clinical trials, enhancing participant safety. Proposals aim to boost CPP stability and professionalism for better biomedical research oversight.
Area of Science:
- Biomedical research ethics
- Clinical trial regulation
- French pharmaceutical law
Background:
- Directive 2001/20/CE mandated changes in French law regarding clinical trials.
- Existing regulations required modifications for enhanced protection of human research participants.
- Biomedical research authorization processes needed alignment with European standards.
Purpose of the Study:
- To outline the legal and ethical modifications in French biomedical research law.
- To detail the new requirements for clinical trial authorization, emphasizing ethical review.
- To propose measures for improving the stability and professionalism of Ethics Committees.
Main Methods:
- Analysis of French legal transpositions of Directive 2001/20/CE.
- Review of regulatory changes concerning biomedical research authorization.
- Examination of the role and function of Committees for the Protection of Persons (CPPs).
Main Results:
- Declaration to authorities now precedes authorization for clinical trials.
- An expressly favorable opinion from a CPP is mandatory before initiating a trial.
- New procedures enhance the protection of individuals in biomedical research.
Conclusions:
- French law now mandates a stricter, ethics-focused approval process for clinical trials.
- The enhanced framework ensures greater participant safety and ethical conduct in research.
- Recommendations are proposed to ensure the consistent quality and reliability of CPPs.